Lack of Association Between Neurohormonal Blockade and Survival in Transthyretin Cardiac Amyloidosis.

ABSTRACT: Background Despite the belief that heart failure therapies are not effective in transthyretin cardiac amyloidosis, data are limited. We tested the association of neurohormonal blockade use with survival. Methods and Results A total of 309 consecutive patients with transthyretin cardiac amyloidosis were identified. Medication inventory was obtained at baseline and subsequent visits. Exposure included a neurohormonal blockade class (β-blocker [βB], angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, and mineralocorticoid antagonist) at baseline and subsequent visits. βB was modeled as baseline use, time-varying use, and in an inverse probability treatment weighted model. Primary outcome was all-cause mortality analyzed with adjusted Cox proportional hazards models. Continui

SUBMITTER: Cheng RK 

PROVIDER: S-EPMC9075255 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature